Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis

Exclusion Criteria

• •Recent (\<6 months before screening) clinically significant bleeding
• •Hemoglobin (Hb) \< 9.0 g/dL at screening
• •Platelet count \< 100 x 10\^9/L
• •aPTT or PT \> ULN (upper limit of normal)
• •Hepatic disease associated with ALT \> 3x ULN, or total bilirubin \>2x ULN with direct bilirubin \> 20% of the total
• •Sustained uncontrolled hypertension (diastolic blood pressure ≥100 mmHg and/or systolic blood pressure ≥ 180 mmHg)
• •Known intracranial neoplasm, arteriovenous malformation or aneurysm
• •Known bleeding disorders e.g. von-Willebrand disease or Hemophilia A, B or C
• •Recent (\<3 months before screening) thromboembolic event, e.g. acute coronary syndrome, stroke or VTE (except dialysis access thrombosis)
• •Recent (\<3 months before screening) major surgery or scheduled major surgery during study participation
• •Scheduled living donor renal transplant during study participation
• •Persistent heart failure as classified by the New York Heart Association (NYHA) classification of 3 or higher
• •Receiving antiplatelet therapy except daily ASA ≤ 150 mg/day
• •Receiving anticoagulation in therapeutic doses, other than standard anticoagulation during the hemodialysis procedure